Type 2 Diabetes Market by Drug Class, Distribution Channel, and Geography - Forecast and Analysis 2023-2027

Published: Nov 2022

Pages: 173

SKU: IRTNTR70605

Snapshot

Type 2 Diabetes Drugs Market Analysis Report 2023-2027:

The type 2 diabetes market size is estimated to grow at a CAGR of 10.94% and the size of the market is forecast to increase by USD 39.37 billion between 2022 and 2027. The growth of the market depends on several factors, including the rising prevalence of diabetes, the rise in the prevalence of obesity and changing lifestyles and recent product approvals, the rising prevalence of diabetes, the rising prevalence of obesity, and changing lifestyles.

This market report extensively covers market segmentation by drug class (insulin, dpp-4 inhibitor, glp-1 receptor agonists, sglt-2 inhibitors, and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies), and geography (North America, Europe, Asia, and Rest of World (ROW). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will the Size of the Type 2 Diabetes Market be During the Forecast Period?

To learn more about this report, Download Report Sample

Type 2 Diabetes Market: Key Drivers, Trends, Challenges, and Customer Landscape

The rising prevalence of diabetes is notably driving the type 2 diabetes (T2D) market growth, although factors such as the low diagnosis rate may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Type 2 Diabetes Market Driver

The increase of diabetes all around the world is the major driver of type 2 diabetes market growth. The body’s ineffective secretion of insulin production is the reason behind the occurrence of type 2 diabetes. Obesity and lack of exercise are the prime cause of type 2 diabetes. Type 2 diabetes is caused by hyperglycemia and metabolic alterations due to abnormalities in insulin secretion or insulin action. Nowadays, type 2 diabetes is not only common in adults but also common among children. It is hard to diagnose early symptoms of type 2 diabetes. As soon as the disease is diagnosed, it is important to provide effective medications. The initial treatment to cure the disease include weight loss plans, lifestyle changes, and the administration of metformin. American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend a patient-specific treatment approach to improve glycemic control to treat the disease. People with type 2 diabetes will drive the growth of the market during the forecast period.

Key Type 2 Diabetes Market Trends

Innovations in therapies are the primary trend driving the type 2 diabetes market growth. Several vendors are introducing advanced therapeutics to treat diabetes. Incretins are GLP-1 and glucose-dependent insulinotropic polypeptides (GIPs), which are secreted by the GI tract in response to food intake. Both GLP-1 and GIPs stimulate the beta cells in the pancreas, which account for 60% of the insulin secreted after a meal. Type 2 diabetes reduces the secretion of GLP-1 and reduces the responsiveness to GIP. The benefits of incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release.

Two incretin-based drug classes are used to treat people with type 2 diabetes, including oral DPP4 inhibitors and GLP-1 receptor agonists. The pathophysiology of type 2 diabetes involves at least seven major organs and tissues, including the brain, liver, pancreas, intestines, kidneys, fat, and muscles. No single medication can cure all seven organs and tissues, which is why most people require more than one medication to treat the disease. Hence, drugs with a unique and complementary mechanism of action (MoA) are required. Therapeutics such as DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, colesevelam, and bromocriptine QR provide therapeutic options with a novel MoA. They also prevent weight gain and reduce the risk of hypoglycemia. Though all these medications are not appropriate for everyone, they offer healthcare providers several options to personalize treatments and optimize healthcare for patients.

Key Type 2 Diabetes Market Challenge

The low diagnosis rate may impede the type 2 diabetes (T2D) market growth. The clinical diagnosis of type 2 diabetes might be delayed up to 12 years after its onset owing to the asymptomatic nature of the disease during its initial phases. According to the rule of halves by Wilber and Barrow, only half of the population with the disease is actually diagnosed with diabetes. Of these people, only half undergo treatment from healthcare professionals. Thus, the number of people receiving treatment and achieving the desired outcomes constitutes only a small proportion of the total population with diabetes.

According to the CDC, in 2018, 34.2 million people in the US, or 10.5% of the US population, had diabetes. Of these 34.2 million adults with diabetes, 26.8 million were diagnosed with diabetes, while 7.3 million people were still undiagnosed. Also, the proportion of undiagnosed diabetes was 30%-40% in Europe in 2019. In addition, as per the report of the International Diabetes Federation (IDF) Africa Region, the continent has the highest proportion of people with undiagnosed diabetes, with 60% of adults living with diabetes unaware of their condition in 2019. In Southeast Asia and Western Pacific, 52.1% of the population with diabetes remains undiagnosed. It has also been estimated that 81.1% of the undiagnosed population is from low- and middle-income countries. Thus, the low diagnosis rate prevents people from getting the necessary treatment, posing a challenge to the type 2 diabetes (T2D) market growth.

Key Type 2 Diabetes Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Type 2 Diabetes Market Customer Landscape

Who are the Major Type 2 Diabetes Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Sanofi SA - The company's key offerings for type 2 diabetes patients in India, offered under its pharmaceuticals segment, include two drugs, namely Lyxumia and Zemiglo. This segment also comprises the commercial operations of the following global franchises: Specialty Care, Diabetes and Cardiovascular, and Established Prescription Products and Generics.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segments in the Type 2 Diabetes Market?

The market share growth by the insulin segment will be significant during the forecast period. The insulin segment of the market is expected to grow rapidly during the forecast period, as regular insulin treatment is the only cure for type 1 diabetes. In type 2 diabetes, insulin is administered when options such as diet, exercise, and oral anti-diabetic drugs fail to maintain optimal blood glucose levels. Factors such as an increase in the population with type 2 diabetes and disease awareness contribute to the growth of the global insulin market. In addition, the rising obese and older population is expected to propel the type 2 diabetes (T2D) market growth.

Get a glance at the market contribution of various segments Request a PDF Sample

The insulin segment showed a gradual increase in market share with USD 13.15 billion in 2017 and continued to grow by 2021. Insulin is a peptide hormone produced by the beta cells of the islets of Langerhans (pancreatic cells). It is produced as preproinsulin, which acts as a precursor for insulin. An increase in R&D for novel mechanisms, as well as a rise in the number of awareness programs and collaborations between academic institutes and industries, is expected to boost the market growth. Eli Lilly, Novo Nordisk, and Sanofi are the major vendors in the market. Lantus, NovoRapid, and Humalog are the top-selling products in the type 2 diabetes (T2D) market growth.

Which are the Key Regions for the Type 2 Diabetes Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is projected to contribute 38% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The growth of the type 2 diabetes market in North America is driven by the increasing prevalence of diabetes in North America. For instance, according to the CDC, in 2018, 34.2 million people belonging to all age groups, or 10.5% of the US population, had diabetes. Out of this, 26.9 million people from all age groups, or 8.2% of the US population, had diabetes that had been diagnosed. The US, Canada, and Mexico have the highest proportion of people with diabetes in the region. The US is the major contributor to revenue in the market due to the large base diabetic population, sophisticated healthcare infrastructure, and growing technological advances. Canada and Mexico follow the US and are next to major revenue generators in North America. The availability of advanced drugs is likely to spur the demand for the type 2 diabetes therapeutics market in these countries.

Parent Market Analysis

Technavio categorizes the global type 2 diabetes market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in research and development (R&D) or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Segment Overview

The type 2 diabetes market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by type, product, distribution channel, and region.

Drug Class Outlook ( USD Billion, 2017 - 2027)
- Insulin
- DPP-4 inhibitor
- GLP-1 receptor agonists
- SGLT-2 inhibitors
- Others
Distribution Channel Outlook ( USD Billion, 2017 - 2027)
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
Region Outlook ( USD Billion, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- APAC
  - China
  - India
- Middle East & Africa
  - Saudi Arabia
  - South Africa
  - Rest of the Middle East & Africa

Type 2 Diabetes Market Scope
Report Coverage	Details
Page number	173
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 10.94%
Market growth 2023-2027	USD 39.37 billion
Market structure	Fragmented
YoY growth (%)	9.49
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key countries	US, Germany, UK, China, and India
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Amgen Inc., AstraZeneca Plc, Baxter International Inc., Biocon Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Daiichi Sankyo Co. Ltd., DM Pharma Marketing Pvt. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Practo Technologies Pvt. Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Tonghua Dongbao Pharmaceutical Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Type 2 Diabetes Market Research Report?

CAGR of the type 2 diabetes (T2D) market growth market during the forecast period.
Detailed information on factors that will drive the growth of the type 2 diabetes (T2D) market growth market between 2023 and 2027
Precise estimation of the size of the type 2 diabetes market size and its contribution to the market in focus on the parent market.
Accurate predictions about upcoming trends and changes in consumer behavior.
Growth of the market industry across North America, Europe, Asia, and the Rest of World (ROW).
A thorough analysis of the market’s competitive landscape and detailed information about vendors.
Comprehensive analysis of factors that will challenge the growth of type 2 diabetes market vendors.

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global type 2 diabetes market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global type 2 diabetes market 2017 - 2021 ($ billion)

4.2 Drug class Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Drug class Segment 2017 - 2021 ($ billion)

4.3 Distribution channel Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ billion)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Drug Class

6.1 Market segments
- Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%)

6.2 Comparison by Drug Class
- Exhibit 32: Chart on Comparison by Drug Class
- Exhibit 33: Data Table on Comparison by Drug Class

6.3 Insulin - Market size and forecast 2022-2027
- Exhibit 34: Chart on Insulin - Market size and forecast 2022-2027 ($ billion)
- Exhibit 35: Data Table on Insulin - Market size and forecast 2022-2027 ($ billion)
- Exhibit 36: Chart on Insulin - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Insulin - Year-over-year growth 2022-2027 (%)

6.4 DPP-4 inhibitor - Market size and forecast 2022-2027
- Exhibit 38: Chart on DPP-4 inhibitor - Market size and forecast 2022-2027 ($ billion)
- Exhibit 39: Data Table on DPP-4 inhibitor - Market size and forecast 2022-2027 ($ billion)
- Exhibit 40: Chart on DPP-4 inhibitor - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on DPP-4 inhibitor - Year-over-year growth 2022-2027 (%)

6.5 GLP-1 receptor agonists - Market size and forecast 2022-2027
- Exhibit 42: Chart on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ billion)
- Exhibit 43: Data Table on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ billion)
- Exhibit 44: Chart on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)

6.6 SGLT-2 inhibitors - Market size and forecast 2022-2027
- Exhibit 46: Chart on SGLT-2 inhibitors - Market size and forecast 2022-2027 ($ billion)
- Exhibit 47: Data Table on SGLT-2 inhibitors - Market size and forecast 2022-2027 ($ billion)
- Exhibit 48: Chart on SGLT-2 inhibitors - Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on SGLT-2 inhibitors - Year-over-year growth 2022-2027 (%)

6.7 Others - Market size and forecast 2022-2027
- Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ billion)
- Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
- Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)

6.8 Market opportunity by Drug Class
- Exhibit 54: Market opportunity by Drug Class ($ billion)

7 Market Segmentation by Distribution Channel

7.1 Market segments
- Exhibit 55: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 56: Data Table on Distribution Channel - Market share 2022-2027 (%)

7.2 Comparison by Distribution Channel
- Exhibit 57: Chart on Comparison by Distribution Channel
- Exhibit 58: Data Table on Comparison by Distribution Channel

7.3 Retail pharmacies - Market size and forecast 2022-2027
- Exhibit 59: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 60: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 61: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 62: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)

7.4 Hospital pharmacies - Market size and forecast 2022-2027
- Exhibit 63: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 64: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 65: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)

7.5 Online pharmacies - Market size and forecast 2022-2027
- Exhibit 67: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 68: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 69: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)

7.6 Market opportunity by Distribution Channel
- Exhibit 71: Market opportunity by Distribution Channel ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 73: Chart on Market share by geography 2022-2027 (%)
- Exhibit 74: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 75: Chart on Geographic comparison
- Exhibit 76: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 77: Chart on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 78: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 79: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 81: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 82: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 83: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Germany - Market size and forecast 2022-2027
- Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.9 China - Market size and forecast 2022-2027
- Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)

9.10 UK - Market size and forecast 2022-2027
- Exhibit 105: Chart on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 106: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 107: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 108: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.11 India - Market size and forecast 2022-2027
- Exhibit 109: Chart on India - Market size and forecast 2022-2027 ($ billion)
- Exhibit 110: Data Table on India - Market size and forecast 2022-2027 ($ billion)
- Exhibit 111: Chart on India - Year-over-year growth 2022-2027 (%)
- Exhibit 112: Data Table on India - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 113: Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 114: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 115: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 116: Overview on factors of disruption

11.4 Industry risks
- Exhibit 117: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 118: Vendors covered

12.2 Market positioning of vendors
- Exhibit 119: Matrix on vendor position and classification

12.3 Amgen Inc.
- Exhibit 120: Amgen Inc. - Overview
- Exhibit 121: Amgen Inc. - Product / Service
- Exhibit 122: Amgen Inc. - Key offerings

12.4 AstraZeneca Plc
- Exhibit 123: AstraZeneca Plc - Overview
- Exhibit 124: AstraZeneca Plc - Product / Service
- Exhibit 125: AstraZeneca Plc - Key news
- Exhibit 126: AstraZeneca Plc - Key offerings

12.5 Biocon Ltd.
- Exhibit 127: Biocon Ltd. - Overview
- Exhibit 128: Biocon Ltd. - Business segments
- Exhibit 129: Biocon Ltd. - Key offerings
- Exhibit 130: Biocon Ltd. - Segment focus

12.6 Boehringer Ingelheim International GmbH
- Exhibit 131: Boehringer Ingelheim International GmbH - Overview
- Exhibit 132: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 133: Boehringer Ingelheim International GmbH - Key news
- Exhibit 134: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 135: Boehringer Ingelheim International GmbH - Segment focus

12.7 Cadila Pharmaceuticals Ltd.
- Exhibit 136: Cadila Pharmaceuticals Ltd. - Overview
- Exhibit 137: Cadila Pharmaceuticals Ltd. - Product / Service
- Exhibit 138: Cadila Pharmaceuticals Ltd. - Key offerings

12.8 Daiichi Sankyo Co. Ltd.
- Exhibit 139: Daiichi Sankyo Co. Ltd. - Overview
- Exhibit 140: Daiichi Sankyo Co. Ltd. - Business segments
- Exhibit 141: Daiichi Sankyo Co. Ltd. - Key news
- Exhibit 142: Daiichi Sankyo Co. Ltd. - Key offerings
- Exhibit 143: Daiichi Sankyo Co. Ltd. - Segment focus

12.9 Eli Lilly and Co.
- Exhibit 144: Eli Lilly and Co. - Overview
- Exhibit 145: Eli Lilly and Co. - Product / Service
- Exhibit 146: Eli Lilly and Co. - Key offerings

12.10 Glenmark Pharmaceuticals Ltd.
- Exhibit 147: Glenmark Pharmaceuticals Ltd. - Overview
- Exhibit 148: Glenmark Pharmaceuticals Ltd. - Product / Service
- Exhibit 149: Glenmark Pharmaceuticals Ltd. - Key offerings

12.11 Merck KGaA
- Exhibit 150: Merck KGaA - Overview
- Exhibit 151: Merck KGaA - Business segments
- Exhibit 152: Merck KGaA - Key news
- Exhibit 153: Merck KGaA - Key offerings
- Exhibit 154: Merck KGaA - Segment focus

12.12 Novartis AG
- Exhibit 155: Novartis AG - Overview
- Exhibit 156: Novartis AG - Business segments
- Exhibit 157: Novartis AG - Key offerings
- Exhibit 158: Novartis AG - Segment focus

12.13 Novo Nordisk AS
- Exhibit 159: Novo Nordisk AS - Overview
- Exhibit 160: Novo Nordisk AS - Business segments
- Exhibit 161: Novo Nordisk AS - Key offerings
- Exhibit 162: Novo Nordisk AS - Segment focus

12.14 Pfizer Inc.
- Exhibit 163: Pfizer Inc. - Overview
- Exhibit 164: Pfizer Inc. - Product / Service
- Exhibit 165: Pfizer Inc. - Key news
- Exhibit 166: Pfizer Inc. - Key offerings

12.15 Sanofi SA
- Exhibit 167: Sanofi SA - Overview
- Exhibit 168: Sanofi SA - Business segments
- Exhibit 169: Sanofi SA - Key news
- Exhibit 170: Sanofi SA - Key offerings
- Exhibit 171: Sanofi SA - Segment focus

12.16 Takeda Pharmaceutical Co. Ltd.
- Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings

12.17 Tonghua Dongbao Pharmaceutical Co. Ltd.
- Exhibit 176: Tonghua Dongbao Pharmaceutical Co. Ltd. - Overview
- Exhibit 177: Tonghua Dongbao Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 178: Tonghua Dongbao Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 179: Inclusions checklist
- Exhibit 180: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 181: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 182: Research methodology
- Exhibit 183: Validation techniques employed for market sizing
- Exhibit 184: Information sources

13.5 List of abbreviations
- Exhibit 185: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

type 2 diabetes market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis